Hill Dickinson advised Praetura Ventures on the deal.
A Liverpool-based chemical technology company helping in the fight against dementia, cancer and respiratory illnesses, has secured £2.25 million in a funding round led by venture capital firms Deepbridge Capital and Praetura Ventures.
Liverpool ChiroChem (LCC) is a chemistry-based contract research organisation (CRO) that develops and manufactures chemical components that are critical to the research and development of new drugs. It supplies chiral small molecules to the global pharmaceutical and biotech research and development sector, helping to accelerate the discovery and development of new drugs across multiple therapeutic areas including dementia, cancer and respiratory conditions.
The company is led by Dr Paul Colbon and supports a global customer base from its research and development headquarters in Liverpool and its manufacturing facility in Taizhou, China. Recent client wins include two of the world’s top five pharmaceutical companies.
Corporate partner Matt Noon (Picture) and associate Katy Oakes, of Hill Dickinson’s Liverpool corporate team, advised Praetura Ventures on the transaction.
Law Firms: Hill Dickinson;
Clients: Praetura Ventures ;